President Biden's Path out of the Pandemic Plan

• Path Out of the Pandemic: President's Biden's COVID-19 Action Plan

• What pharmacists need to know: Biden's Path out of the Pandemic

NCPA Member Summaries

• NCPA Advocacy: Getting results that matter for community pharmacy during the national COVID-19 pandemic.

• NCPA Member Summary of COVID-19 Relief Package

• HHS Advisory Opinion on Pharmacist Testing Authority

• CMS Interim Final Rule: Additional Policy and Regulatory Revisions in Response to COVID-19

• CMS Guidance to Medicare Advantage & Part D Plans

• Paycheck Protection Program & Health Care Enhancement Act

• CARES Act Provider Relief Fund

• CARES Act

• Families First Coronavirus Response Act

State and Local Resources

• Letter to State Medicaid Directors Template to Ensure Access to COVID-19 Oral Antivirals

• State Response on COVID-19 Testing & Vaccines - Download Spreadsheet

• State Covid Flexibilities & Emergency Order Experation Dates - Download Spreadsheet

• State CLIA-waiver requirements - Download Spreadsheet

• Model State Audit Prohibition

• Model State MAC and Reimbursement

• Updated state information from NASPA

• State and Local Covid-19 Response Information from MultiState Associates

• Medicaid

• National Governors Association (NGA)

• National Boards of Pharmacy (NABP)

• Joint Letter to Pennsylvania Governor regarding onerous state testing requirements

• List of emergency and temporary orders, policies, and board statements by state

• Contact your state and local officials

NCPA Letters and Comments

• Statement for the Record: The National Community Pharmacists Association (NCPA)United States House Committee on Energy and Commerce Subcommittee on Health Legislative Hearing: "Booster Shot: Enhancing Public Health through Vaccine Legislation"

• Paycheck Protection Program Association Letter

• NCPA Letter to the National Association of Insurance Commissioners Regarding COVID-19

• NCPA Letter to the National Council of Insurance Legislators Regarding COVID-19

• NCPA Letter to the National Governors Association Regarding COVID-19

• Joint Letter to PCMA

• Comments to FDA to clarify Policy for Temporary Compounding of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency Immediately in Effect Guidance for Industry

• Joint Letter to FDA: Compounding Products in Shortage or Anticipated to be in Shortage

• NCPA Letter to Congress

• NCPA Letter to Department of Labor

• NCPA Letter to U.S. Department of Health & Human Services Regarding (COVID‐19)

• NCPA Letter to Vice President Mike Pence - Community Pharmacists' Recommendations to the President's Coronavirus Task Force

• NCPA Letter to CMS Seema Verma

  • NCPA CMS Letter 1 (3/18/2020)

  • NCPA CMS Letter 2 (3/22/2020)

  • NCPA CMS Letter 3 (3/24/2020)

• NCPA Letter to CMS on Testing Reimbursement

General

• Joint Letter to Congress Regarding Funding Health Resource & Services Administration’s (HRSA) COVID-19 Uninsured Program

• Stakeholder Letter to Congress Urging Access to COVID-19 Testing and Treatments

• 114 Members of Congress ask for DIR fee relief

• 84 Percent of Local Pharmacists Say Patients Should Have Access to Experimental COVID-19 Treatment Even as States Move to Restrict

• Pharmacists as Front-Line Responders for Covid-19 Patient Care from Joint Commission of Pharmacy Practitioners (JCPP)

• Resources for Small Businesses from the Small Business Administration (SBA)

• Opportunity for Enhanced Dispensing Fees/Supplemental Payments for Home Delivery in Medicaid

  • Summary of the CMS guidance (NCPA drafted)

  • Draft letter you can send your Medicaid agency urging them to apply for this waiver (NCPA drafted)

  • CMS Medicaid-disaster-relief-SPA template for Medicaid officials

  • Letter from CMS to state Medicaid directors

  • CMS press release on this initiative

  • Medicaid Delivery State Package

  • FFCRA Increased FMAP FAQs